Multiple Sclerosis clinical trials at UC Irvine
2 in progress, 1 open to eligible people
Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
open to eligible people ages 18-55
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.
Irvine, California and other locations
Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
Sorry, in progress, not accepting new patients
This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks in participants with PPMS, in comparison to the approved 600 mg dose of ocrelizumab.
Irvine, California and other locations
Last updated: